Despite meaningful incremental improvements in screening, local treatment and adjuvant therapies, including endocrine therapies (AETs), estrogen receptor (ER)-positive breast cancer (BC) remains associated with a significant long-term risk of late relapse. The gene discussed is ESR1; the disease is breast carcinoma.